A trusted partner to over 20,000 orthopaedic specialists across India, we deliver comprehensive pain management solutions for osteoporosis and osteoarthritis.
Cadila Pharma ranks 10th nationally, maintaining a strong market presence dedicated to better patient outcomes.
India has a growing proportion of the elderly. Ageing leads to more degenerative joint disease (osteoarthritis, osteoporosis), driving an increasing need for advanced orthopaedic care, from joint replacements and fracture management to complex trauma interventions. Rising cases of road accidents, falls, and open fractures further underscore the urgency for timely and effective orthopaedic treatment. Urbanisation, sedentary lifestyle, obesity, and more, lead to earlier degeneration of joints and more musculoskeletal problems, which shows increasing demand for bone management options.
Our therapeutic focus
We have established our presence in the orthopaedic segment, offering a wide range of solutions.
Osteoporosis is a progressive bone disease characterised by decreased bone density and quality, leading to increased fracture risk. It typically progresses without symptoms until a fracture occurs, making early detection crucial. Approximately 61 million people in India suffer from osteoporosis, with 80% of them being women. This prevalence is notably higher than in Western countries, with Indians experiencing peak incidence 10–20 years earlier. Our portfolio for this disease burden consists of:
Osteoarthritis (OA) is emerging as a significant public health concern in India, with its prevalence and impact steadily increasing over the past few decades. This degenerative joint disease, particularly affecting the knees, hips, and hands, is now among the leading causes of disability in the country. The number of individuals living with OA in India surged from approximately 23.5 million in 1990 to over 62 million by 2019. The age-standardised prevalence increased from 4,895 to 5,313 per 100,000 persons during the same period. Disability-Adjusted Life Years (DALYs) due to OA more than doubled, from 0.79 million in 1990 to 2.12 million in 2019. We support patients with our portfolio of:
Orthopaedic pain refers to pain originating from the musculoskeletal system, which includes bones, joints, muscles, ligaments, tendons, and nerves. It can result from injury, overuse, inflammation, degenerative conditions, or other underlying issues affecting these structures.
We are committed to holistic orthopaedic care from classes to masses, reaching out to all strata of society with our brand portfolio:
Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication.
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
